PWA
RIGL icon

Physician Wealth Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Physician Wealth Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-50
Closed -$900 – 1946
2025
Q1 		$900 Buy
+50
New +$1.01K ﹤0.01% 1162

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLGM
Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Physician Wealth Advisors's RIGL Position: Q2 2025 in Review

Physician Wealth Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q2 2025, closing a stake of 50 shares — an estimated $900 sold.

Physician Wealth Advisors first reported a position in RIGL in Q1 2025 and held it in 1 quarter. The position peaked at $900 in Q1 2025. 125 funds tracked by Wall St. Rank hold RIGL as of Q2 2025.

  • Physician Wealth Advisors reported no remaining Rigel Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Physician Wealth Advisors sold 50 Rigel Pharmaceuticals shares in Q2 2025, an estimated $900.
  • Physician Wealth Advisors first reported a position in Rigel Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Physician Wealth Advisors's Rigel Pharmaceuticals position peaked at $900 in Q1 2025.
  • 125 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2025.

Based on Physician Wealth Advisors's 13F filing for Q2 2025, filed 14 Jul 2025.